Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
2 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
4 African trypanosomiasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
5 African trypanosomiasis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
6 African trypanosomiasis 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
7 African trypanosomiasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
8 African trypanosomiasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
14 Alcoholic liver disease 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
15 Alcoholic liver disease 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
16 Alcoholic liver disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
17 Alcoholic liver disease 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
18 Alcoholic liver disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
19 Alcoholic liver disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
20 Allograft rejection 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
21 Allograft rejection 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
22 Allograft rejection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
23 Allograft rejection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
24 Alzheimer disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
25 Alzheimer disease 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
26 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
27 Alzheimer disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
28 Alzheimer disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
29 Amoebiasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
30 Amoebiasis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
31 Amoebiasis 💬
 2件: IL1R1, IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
32 Amoebiasis 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
33 Amoebiasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
34 Amoebiasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
35 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
36 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
37 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
38 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
39 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
40 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
41 Antifolate resistance 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
42 Antifolate resistance 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
43 Antifolate resistance 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
44 Antifolate resistance 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
45 Antigen processing and presentation 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
46 Antigen processing and presentation 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
47 Apoptosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
48 Apoptosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
49 Asthma 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
50 Asthma 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
51 Autoimmune thyroid disease 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
52 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
53 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
54 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
55 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
56 C-type lectin receptor signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
57 C-type lectin receptor signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
58 C-type lectin receptor signaling pathway 💬
 1件: IL23A 💬 D10438 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
59 C-type lectin receptor signaling pathway 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
60 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
61 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
62 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
63 Calcium signaling pathway 💬
 2件: EDNRA, EDNRB 💬 D01227 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
64 Calcium signaling pathway 💬
 2件: EDNRA, EDNRB 💬 D07538 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
65 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
66 cAMP signaling pathway 💬
 1件: EDNRA 💬 D01227 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
67 cAMP signaling pathway 💬
 1件: EDNRA 💬 D07538 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
68 Cell adhesion molecules 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
69 Cell adhesion molecules 💬
 1件: PDCD1 💬 D10316 💬 Nivolumab 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬
70 Cellular senescence 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
71 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
72 cGMP-PKG signaling pathway 💬
 2件: EDNRA, EDNRB 💬 D01227 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
73 cGMP-PKG signaling pathway 💬
 2件: EDNRA, EDNRB 💬 D07538 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
74 cGMP-PKG signaling pathway 💬
 1件: OPRD1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
75 cGMP-PKG signaling pathway 💬
 1件: OPRD1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
76 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
77 Chagas disease 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
78 Chagas disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
79 Chagas disease 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
80 Chagas disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
81 Chagas disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
82 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
83 Chemical carcinogenesis - receptor activation 💬
 1件: VDR 💬 D01518 💬 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238 💬
84 Chemokine signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
85 Cholinergic synapse 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
86 Coronavirus disease - COVID-19 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
87 Coronavirus disease - COVID-19 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
88 Coronavirus disease - COVID-19 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
89 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
90 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
91 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
92 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
93 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
94 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
95 Cytokine-cytokine receptor interaction 💬
 1件: CSF2RA 💬 D09930 💬 Mavrilimumab 2件: 41, 46 💬
96 Cytokine-cytokine receptor interaction 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
97 Cytokine-cytokine receptor interaction 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
98 Cytokine-cytokine receptor interaction 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
99 Cytokine-cytokine receptor interaction 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
100 Cytokine-cytokine receptor interaction 💬
 2件: IL1R1, IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
101 Cytokine-cytokine receptor interaction 💬
 1件: IL23A 💬 D10438 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
102 Cytokine-cytokine receptor interaction 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
103 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
104 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
105 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
106 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
107 Cytosolic DNA-sensing pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
108 Cytosolic DNA-sensing pathway 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
109 Dilated cardiomyopathy 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
110 Dilated cardiomyopathy 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
111 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
112 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
113 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
114 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
115 EGFR tyrosine kinase inhibitor resistance 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
116 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
117 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: VDR 💬 D01518 💬 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238 💬
118 Epstein-Barr virus infection 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
119 Epstein-Barr virus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
120 Epstein-Barr virus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
121 Epstein-Barr virus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
122 Epstein-Barr virus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
123 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
124 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
125 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
126 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
127 Fluid shear stress and atherosclerosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
128 Fluid shear stress and atherosclerosis 💬
 2件: IL1R1, IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
129 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
130 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
131 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
132 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
133 FoxO signaling pathway 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
134 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
135 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
136 Graft-versus-host disease 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
137 Graft-versus-host disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
138 Graft-versus-host disease 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
139 Graft-versus-host disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
140 Graft-versus-host disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
141 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
142 Hematopoietic cell lineage 💬
 1件: CSF2RA 💬 D09930 💬 Mavrilimumab 2件: 41, 46 💬
143 Hematopoietic cell lineage 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
144 Hematopoietic cell lineage 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
145 Hematopoietic cell lineage 💬
 2件: IL1R1, IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
146 Hematopoietic cell lineage 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
147 Hematopoietic cell lineage 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
148 Hematopoietic cell lineage 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
149 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 D02994 💬 Rituximab 49件:  6 , 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
150 Hematopoietic cell lineage 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
151 Hematopoietic cell lineage 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
152 Hepatitis B 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
153 Hepatitis B 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
154 Hepatitis B 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
155 Hepatitis B 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
156 Hepatitis B 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
157 Hepatitis C 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
158 Hepatitis C 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
159 Hepatitis C 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
160 Hepatitis C 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
161 Herpes simplex virus 1 infection 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
162 Herpes simplex virus 1 infection 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
163 Herpes simplex virus 1 infection 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
164 Herpes simplex virus 1 infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
165 Herpes simplex virus 1 infection 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
166 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
167 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
168 HIF-1 signaling pathway 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
169 HIF-1 signaling pathway 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
170 HIF-1 signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
171 Human cytomegalovirus infection 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
172 Human cytomegalovirus infection 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
173 Human cytomegalovirus infection 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
174 Human cytomegalovirus infection 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
175 Human cytomegalovirus infection 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
176 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
177 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
178 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
179 Human cytomegalovirus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
180 Human cytomegalovirus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
181 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
182 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
183 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
184 Human papillomavirus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
185 Human papillomavirus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
186 Human papillomavirus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
187 Human papillomavirus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
188 Human T-cell leukemia virus 1 infection 💬
 1件: FDPS 💬 D00939 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
189 Human T-cell leukemia virus 1 infection 💬
 1件: FDPS 💬 D07119 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
190 Human T-cell leukemia virus 1 infection 💬
 2件: IL1R1, IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
191 Human T-cell leukemia virus 1 infection 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
192 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
193 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
194 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
195 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
196 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
197 Hypertrophic cardiomyopathy 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
198 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
199 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
200 IL-17 signaling pathway 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
201 IL-17 signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
202 IL-17 signaling pathway 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
203 IL-17 signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
204 IL-17 signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
205 Inflammatory bowel disease 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
206 Inflammatory bowel disease 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
207 Inflammatory bowel disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
208 Inflammatory bowel disease 💬
 1件: IL23A 💬 D10438 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
209 Inflammatory bowel disease 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
210 Inflammatory bowel disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
211 Inflammatory bowel disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
212 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
213 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
214 Influenza A 💬
 1件: FDPS 💬 D00939 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
215 Influenza A 💬
 1件: FDPS 💬 D07119 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
216 Influenza A 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
217 Influenza A 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
218 Influenza A 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
219 Influenza A 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
220 Influenza A 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
221 Influenza A 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
222 Influenza A 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
223 Insulin resistance 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
224 Insulin resistance 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
225 Insulin resistance 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
226 Intestinal immune network for IgA production 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
227 Intestinal immune network for IgA production 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
228 JAK-STAT signaling pathway 💬
 1件: CSF2RA 💬 D09930 💬 Mavrilimumab 2件: 41, 46 💬
229 JAK-STAT signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
230 JAK-STAT signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
231 JAK-STAT signaling pathway 💬
 1件: IL23A 💬 D10438 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
232 JAK-STAT signaling pathway 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
233 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
234 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
235 JAK-STAT signaling pathway 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
236 JAK-STAT signaling pathway 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
237 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
238 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
239 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
240 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
241 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
242 Legionellosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
243 Legionellosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
244 Legionellosis 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
245 Legionellosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
246 Legionellosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
247 Leishmaniasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
248 Leishmaniasis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
249 Leishmaniasis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
250 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
251 Leishmaniasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
252 Leishmaniasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
253 Lipid and atherosclerosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
254 Lipid and atherosclerosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
255 Lipid and atherosclerosis 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
256 Lipid and atherosclerosis 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
257 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
258 Lipid and atherosclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
259 Lipid and atherosclerosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
260 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
261 Malaria 💬
 1件: IL12A 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
262 Malaria 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
263 Malaria 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
264 Malaria 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
265 Malaria 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
266 MAPK signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
267 MAPK signaling pathway 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
268 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
269 MAPK signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
270 MAPK signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
271 Measles 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
272 Measles 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
273 Measles 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
274 Measles 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
275 Measles 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
276 Melanogenesis 💬
 1件: EDNRB 💬 D01227 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
277 Melanogenesis 💬
 1件: EDNRB 💬 D07538 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
278 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
279 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
280 Metabolic pathways 💬
 1件: FDPS 💬 D00939 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
281 Metabolic pathways 💬
 1件: FDPS 💬 D07119 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
282 Mineral absorption 💬
 1件: VDR 💬 D01518 💬 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238 💬
283 Morphine addiction 💬
 1件: OPRM1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
284 Morphine addiction 💬
 1件: OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
285 mTOR signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
286 mTOR signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
287 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
288 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
289 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
290 Necroptosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
291 Necroptosis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
292 Necroptosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
293 Necroptosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
294 Necroptosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
295 Neuroactive ligand-receptor interaction 💬
 2件: EDNRA, EDNRB 💬 D01227 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
296 Neuroactive ligand-receptor interaction 💬
 2件: EDNRA, EDNRB 💬 D07538 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
297 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00088 💬 Hydrocortisone 11件:  6 , 41, 46, 53, 75, 78, 81, 83, 97, 98, 299 💬
298 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00407 💬 Methylprednisolone 48件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 💬
299 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00751 💬 Methylprednisolone 48件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 💬
300 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00979 💬 Methylprednisolone 48件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 💬
301 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D05000 💬 Methylprednisolone 48件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 💬
302 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D05001 💬 Methylprednisolone 48件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 💬
303 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D05002 💬 Methylprednisolone 48件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 💬
304 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00472 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
305 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00980 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
306 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00981 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
307 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00982 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
308 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D01239 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
309 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D01998 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
310 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D02156 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
311 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D03301 💬 Prednisolone 43件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 💬
312 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00473 💬 Prednisone 48件:  2 ,  6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬
313 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D08416 💬 Prednisone acetate 7件: 35, 40, 41, 46, 49, 162, 224 💬
314 Neuroactive ligand-receptor interaction 💬
 3件: OPRD1, OPRK1, OPRM1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
315 Neuroactive ligand-receptor interaction 💬
 3件: OPRD1, OPRK1, OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
316 NF-kappa B signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
317 NF-kappa B signaling pathway 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
318 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
319 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
320 NOD-like receptor signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
321 NOD-like receptor signaling pathway 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
322 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
323 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
324 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
325 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
326 Non-alcoholic fatty liver disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
327 Non-alcoholic fatty liver disease 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
328 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
329 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
330 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
331 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
332 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
333 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
334 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
335 Osteoclast differentiation 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
336 Osteoclast differentiation 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
337 Osteoclast differentiation 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
338 Osteoclast differentiation 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
339 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
340 Osteoclast differentiation 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
341 Osteoclast differentiation 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
342 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
343 Pancreatic cancer 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
344 Pancreatic cancer 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
345 Parathyroid hormone synthesis, secretion and action 💬
 1件: VDR 💬 D01518 💬 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238 💬
346 Pathogenic Escherichia coli infection 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
347 Pathogenic Escherichia coli infection 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
348 Pathogenic Escherichia coli infection 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
349 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
350 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
351 Pathways in cancer 💬
 1件: CSF2RA 💬 D09930 💬 Mavrilimumab 2件: 41, 46 💬
352 Pathways in cancer 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
353 Pathways in cancer 💬
 2件: EDNRA, EDNRB 💬 D01227 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
354 Pathways in cancer 💬
 2件: EDNRA, EDNRB 💬 D07538 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
355 Pathways in cancer 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
356 Pathways in cancer 💬
 1件: IL23A 💬 D10438 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
357 Pathways in cancer 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
358 Pathways in cancer 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
359 Pathways in cancer 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
360 Pathways in cancer 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
361 Pathways in cancer 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
362 Pathways of neurodegeneration - multiple diseases 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
363 Pathways of neurodegeneration - multiple diseases 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
364 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
365 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
366 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
367 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
368 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
369 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: PDCD1 💬 D10316 💬 Nivolumab 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬
370 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
371 Pertussis 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
372 Pertussis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
373 Pertussis 💬
 1件: IL23A 💬 D10438 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
374 Pertussis 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
375 Pertussis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
376 Pertussis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
377 PI3K-Akt signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
378 PI3K-Akt signaling pathway 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
379 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
380 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
381 PI3K-Akt signaling pathway 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
382 PI3K-Akt signaling pathway 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
383 Prion disease 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
384 Prion disease 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
385 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
386 Prion disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
387 Prion disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
388 Prolactin signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
389 Prostate cancer 💬
 1件: IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
390 Proteoglycans in cancer 💬
 1件: IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
391 Proteoglycans in cancer 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
392 Proteoglycans in cancer 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
393 Relaxin signaling pathway 💬
 1件: EDNRB 💬 D01227 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
394 Relaxin signaling pathway 💬
 1件: EDNRB 💬 D07538 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
395 Renin secretion 💬
 1件: EDNRA 💬 D01227 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
396 Renin secretion 💬
 1件: EDNRA 💬 D07538 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
397 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
398 Rheumatoid arthritis 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
399 Rheumatoid arthritis 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
400 Rheumatoid arthritis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
401 Rheumatoid arthritis 💬
 1件: IL23A 💬 D10438 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
402 Rheumatoid arthritis 💬
 1件: IL23A 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
403 Rheumatoid arthritis 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
404 Rheumatoid arthritis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
405 Rheumatoid arthritis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
406 RIG-I-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
407 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
408 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
409 Salmonella infection 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
410 Salmonella infection 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
411 Salmonella infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
412 Salmonella infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
413 Shigellosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
414 Shigellosis 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
415 Shigellosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
416 Shigellosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
417 Signaling pathways regulating pluripotency of stem cells 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
418 Signaling pathways regulating pluripotency of stem cells 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
419 Sphingolipid signaling pathway 💬
 1件: OPRD1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
420 Sphingolipid signaling pathway 💬
 1件: OPRD1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
421 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
422 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
423 Systemic lupus erythematosus 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
424 Systemic lupus erythematosus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
425 Systemic lupus erythematosus 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
426 T cell receptor signaling pathway 💬
 1件: PDCD1 💬 D10316 💬 Nivolumab 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬
427 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
428 T cell receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
429 T cell receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
430 Terpenoid backbone biosynthesis 💬
 1件: FDPS 💬 D00939 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
431 Terpenoid backbone biosynthesis 💬
 1件: FDPS 💬 D07119 💬 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299 💬
432 TGF-beta signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
433 TGF-beta signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
434 Th1 and Th2 cell differentiation 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
435 Th1 and Th2 cell differentiation 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
436 Th1 and Th2 cell differentiation 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
437 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
438 Th17 cell differentiation 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
439 Th17 cell differentiation 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
440 Th17 cell differentiation 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
441 Th17 cell differentiation 💬
 1件: IL23A 💬 D10438 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
442 Th17 cell differentiation 💬
 1件: IL23A 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
443 Th17 cell differentiation 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
444 Th17 cell differentiation 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
445 Th17 cell differentiation 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
446 Th17 cell differentiation 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
447 Th17 cell differentiation 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
448 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
449 TNF signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
450 TNF signaling pathway 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
451 TNF signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
452 TNF signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
453 Toll-like receptor signaling pathway 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
454 Toll-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
455 Toll-like receptor signaling pathway 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
456 Toll-like receptor signaling pathway 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
457 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
458 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
459 Toxoplasmosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
460 Toxoplasmosis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
461 Toxoplasmosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
462 Toxoplasmosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
463 Toxoplasmosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
464 Transcriptional misregulation in cancer 💬
 1件: CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
465 Transcriptional misregulation in cancer 💬
 1件: IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
466 Transcriptional misregulation in cancer 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
467 Tuberculosis 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
468 Tuberculosis 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
469 Tuberculosis 💬
 1件: IL23A 💬 D10438 💬 Guselkumab 5件: 37, 41, 51, 96, 97 💬
470 Tuberculosis 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
471 Tuberculosis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
472 Tuberculosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
473 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
474 Tuberculosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
475 Tuberculosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
476 Tuberculosis 💬
 1件: VDR 💬 D01518 💬 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238 💬
477 Type I diabetes mellitus 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
478 Type I diabetes mellitus 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
479 Type I diabetes mellitus 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
480 Type I diabetes mellitus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
481 Type I diabetes mellitus 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
482 Type II diabetes mellitus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
483 Type II diabetes mellitus 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
484 Vascular smooth muscle contraction 💬
 1件: EDNRA 💬 D01227 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
485 Vascular smooth muscle contraction 💬
 1件: EDNRA 💬 D07538 💬 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
486 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
487 Viral carcinogenesis 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 💬
488 Viral carcinogenesis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
489 Viral myocarditis 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
490 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
491 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
492 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
493 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
494 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
495 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
496 Yersinia infection 💬
 1件: IL1B 💬 D09911 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
497 Yersinia infection 💬
 1件: IL6 💬 D10080 💬 Sirukumab 2件: 41, 46 💬
498 Yersinia infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
499 Yersinia infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬

先頭へ